Interaction Color Code
Clinical Bottom Line
Minimal data to guide interaction: weigh risks and benefits of using this combination
Drug 1
Drug 1 dose
150 mg elvitegravir / 150 mg cobicistat once daily
Drug 1 effect
Cmax and AUC decreased 7%; Cmin decreased 3%
Drug 2
Drug 2 dose
400 / 100 mg once daily
Drug 2 effect
Velpatasvir Cmax increased 5%, AUC increased 19%, Cmin increased 37%; Sofosbuvir Cmax increased 1%, AUC increased 24%; Sofosbuvir metabolite Cmax increased 13%, AUC increased 35%, Cmin increased 45%
Clinical Effects
Stribild is coformulated with tenofovir disoproxil fumarate and TDF levels are increased by sofosbuvir / velpatasvir.
Management
May coadminister with caution. Monitor for adverse reactions associated with TDF
Import ID
139
